Lab Study Finds Compound Stops 90% of Pancreatic Cancer Cell Migration
By
David Nield
Summary
Researchers at Florida A&M University have discovered that compounds called polyisoprenylated cysteinyl amide inhibitors can stop 90% of pancreatic cancer cell migration in lab tests. This is significant because pancreatic ductal adenocarcinoma, driven by KRAS gene mutations, has been notoriously difficult to treat — with KRAS long considered "undruggable." The study offers a potential new approach to tackling one of the deadliest cancers.
Source
Twitter / XLab Study Finds Compound Stops 90% of Pancreatic Cancer Cell Migrationsciencealert.comKey quotes
· 3 pulledThey've long been considered so challenging to treat that KRAS has been labeled 'undruggable' across decades of prior research.
Now, a new lab study points to a possible way around that problem.
A team from Florida A&M University College of Pharmacy and Pharmaceutical Sciences has been testing compounds called polyisoprenylated cysteinyl amide
You might also wanna read
Scientists discover an unexpected way to make pancreatic cancer cells self-destruct
Combination therapy with RAS inhibitors shows promise for pancreatic cancer regression and resistance prevention
This research article presents a study on a targeted combination therapy for pancreatic ductal adenocarcinoma (PDAC), one of the deadliest c
pnas.org·24d ago
Experimental daraxonrasib pill extends survival for advanced pancreatic cancer patients, study finds
An experimental pill called daraxonrasib has shown promise in helping patients with advanced pancreatic cancer live longer. The drug blocks
bit.ly·1mo ago
Experimental pill daraxonrasib nearly doubles survival time in advanced pancreatic cancer trial
A novel experimental pill called daraxonrasib has shown promise in extending survival for patients with advanced pancreatic cancer. The drug
chicagotribune.com·1mo agoExperimental pill daraxonrasib nearly doubles survival time in advanced pancreatic cancer trial
A novel experimental pill called daraxonrasib has shown promise in extending survival for patients with advanced pancreatic cancer. The drug
chicagotribune.com·1mo ago
Experimental pill daraxonrasib nearly doubles survival time in advanced pancreatic cancer patients
A novel experimental pill called daraxonrasib has shown promise in extending survival for patients with advanced pancreatic cancer. The drug
chicagotribune.com·1mo ago
Experimental pill daraxonrasib extends survival in advanced pancreatic cancer patients, study finds
Researchers reported that daraxonrasib, a novel experimental pill, helped patients with advanced pancreatic cancer live longer by blocking a
npr.org·1mo ago
Comments
Sign in to join the conversation.
No comments yet. Be the first.